Crescendo Biologics, a life sciences spin-out company of the Babraham Institute, has received £17.5m ($28.9m) in a series A supported by new and existing backers, including the corporate venturing arm of Astellas Pharma.

The round was led by Imperial Innovations, the tech transfer unit of Imperial College London, marking the latest in a string of deals between Innovations and Cambridge startups. Crescendo also attracted new investor Astellas Venture Management as well as seed round investor venture firm Sofinnova Partners. As…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?